ReviewLife (Basel, Switzerland)2022
Post-COVID-19 Condition: Where Are We Now?
Review in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Evolutionary Predictors of Post-COVID Syndrome.Journal of clinical medicine · 2026Article
- Symptom-based clusters in people with post-COVID-19 condition (PCC).Journal of translational medicine · 2026Article
- [Herbal treatment options for post-viral symptoms and long COVID].Wiener medizinische Wochenschrift (1946) · 2026Review
- DNA methylation changes in thyroid cancer patients infected with SARS-CoV-2.Updates in surgery · 2026Article
- Relationship between long covid and functional disability in adults and the seniors in the south of Brazil.BMC public health · 2025Article
- Effect of Yoga on Pulmonary Function Tests and Arterial Stiffness in Post-COVID-19 Mild Moderate Cases.Maedica · 2025Article
- Exploring long COVID in pediatric patients: clinical insights from a long COVID clinic.Frontiers in pediatrics · 2025Article
- Comparative analysis of clinical profile, laboratory profile and outcome in COVID-19 patients with and without hypothyroidism.Ghana medical journal · 2024Observational
- The Potential Role of Virus Infection in the Progression of Thyroid Cancer.World journal of oncology · 2024Review
- Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis.World journal of virology · 2024Article
- Long COVID or Post-COVID-19 Condition: Past, Present and Future Research Directions.Microorganisms · 2023Review
- SARS-CoV-2 and thyroid diseases.Journal of translational autoimmunity · 2023Review
- Beyond Acute COVID-19: Investigating the Incidence of Subacute Thyroiditis in Long COVID-19 in Korea.Endocrinology and metabolism (Seoul, Korea) · 2023Article
- Comorbidities of COVID-19 Patients.Medicina (Kaunas, Lithuania) · 2023Review
- Cerebral Vasomotor Reactivity in COVID-19: A Narrative Review.Life (Basel, Switzerland) · 2023Review
- Utility of Serum Ferritin for Predicting Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Patients with Long COVID.Journal of clinical medicine · 2023Article
- Subclinical Hypothyroidism among Patients with COVID-19 Infection in a Tertiary Care Centre: A Descriptive Cross-sectional Study.JNMA; journal of the Nepal Medical Association · 2023Article
- The pathophysiology of postacute sequelae of COVID-19 (PASC): Possible role for persistent inflammation.Asia Pacific allergy · 2023Review
- Long-Term Follow-Up of Patients Needing Extracorporeal Membrane Oxygenation Following a Critical Course of COVID-19.Life (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is currently considered a systemic infection involving multiple systems and causing chronic complications. Compared to other post-viral fatigue syndromes, these complications are wider and more intense. The most frequent symptoms are profound fatigue, dyspnea, sleep difficulties, anxiety or depression, reduced lung capacity, memory/cognitive impairment, and hyposmia/anosmia. Risk factors for this condition are severity of illness, more than five symptoms in the first week of the disease, female sex, older age, the presence of comorbidities, and a weak anti-SARS-CoV-2 antibody response. Different lines of research have attempted to explain these protracted symptoms; chronic persistent inflammation, autonomic nervous system disruption, hypometabolism, and autoimmunity may play a role. Due to thyroid high ACE expression, the key molecular complex SARS-CoV-2 uses to infect the host cells, thyroid may be a target for the coronavirus infection. Thyroid dysfunction after SARS-CoV-2 infection may be a combination of numerous mechanisms, and its role in long-COVID manifestations is not yet established. The proposed mechanisms are a direct effect of SARS-CoV-2 on target cells, an indirect effect of systemic inflammatory immune response, and a dysfunction of the hypothalamic-pituitary-thyroid (HPT) axis leading to decreased serum TSH. Only a few studies have reported the thyroid gland status in the post-COVID-19 condition. The presence of post-COVID symptoms deserves recognition of COVID-19 as a cause of post-viral fatigue syndrome. It is important to recognize the affected individuals at an early stage so we can offer them the most adequate treatments, helping them thrive through the uncertainty of their condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.